Vitamin D receptor polymorphisms in hypertensive disorders of pregnancy by Rezende, Vania B. et al.
  Universidade de São Paulo
 
2012
 
Vitamin D receptor polymorphisms in
hypertensive disorders of pregnancy
 
 
MOLECULAR BIOLOGY REPORTS, DORDRECHT, v. 39, n. 12, pp. 10903-10906, DEC, 2012
http://www.producao.usp.br/handle/BDPI/42706
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Farmacologia - FMRP/RFA Artigos e Materiais de Revistas Científicas - FMRP/RFA
Vitamin D receptor polymorphisms in hypertensive disorders
of pregnancy
Vania B. Rezende • Valeria C. Sandrim •
Ana C. Palei • Lorena Machado • Ricardo C. Cavalli •
Geraldo Duarte • Jose E. Tanus-Santos
Received: 20 June 2012 / Accepted: 1 October 2012 / Published online: 7 October 2012
 Springer Science+Business Media Dordrecht 2012
Abstract Hypertension is the most common medical
disorder in pregnancy, and a leading cause of maternal and
neonatal morbidity and mortality. Vitamin D endocrine
system has important influence on immune modulation and
endothelial function, which play a role in preeclampsia
(PE) and gestational hypertension (GH). Vitamin D
receptor (VDR) is present in a large variety of cell types,
including placental cells. We examined whether there is an
association between VDR polymorphisms (FokI, ApaI and
BsmI) with PE or with GH. Restriction fragment length
polymorphism techniques were used to genotype 529
pregnant (154 with GH, 162 with PE, and 213 healthy
pregnant—HP). VDR haplotype frequencies were inferred
using the PHASE 2.1 program. We found similar genotype
distributions for the three VDR polymorphisms in both PE
and GH groups compared with the HP group (all P [ 0.05).
In parallel with these findings, the VDR haplotype
frequency distribution was similar in both PE and GH
groups compared with the HP group (all P [ 0.05). Our
results showing no significant association between VDR
polymorphisms or haplotypes with PE or GH suggest that
genetic variations in VDR do not predispose to hyperten-
sive disorders of pregnancy.
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Introduction
Hypertension is one of the most common causes of maternal
death worldwide, and may typically manifest as gestational
hypertension (GH) or preeclampsia (PE). The pathophysi-
ology of hypertensive disorders of pregnancy has not been
completely clarified. However, there is evidence indicating
that preeclampsia is associated with vitamin D deficiency
[1–3]. Indeed, vitamin D plays important roles not only in
bone health, but also in both cardiovascular and immune
systems alterations during pregnancy [4–8]. Vitamin D
undergoes hydroxylation in the maternal liver to form
25-OH-vitamin D (25OH-D), which is an inactive form of
this hormone [9]. The active form of vitamin D (1,25-
[OH]2D) results from the activity of 1-a-hydroxylase,
mainly in the kidneys, and it is now known that this is also
important in the placenta in pregnant women [2, 10].
1,25(OH)2D concentrations increase in a healthy gestation,
and this critical to supply calcium for fetal growth [4].
However, several studies reported reduced maternal vitamin
D serum levels in preeclampsia, and this alteration may be a
consequence of impaired placentation [3, 10–13].
1,25-[OH]2D exerts its effects by interacting with vitamin
D receptor (VDR) [9]. Since the discovery of the VDR gene,
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common single nucleotide polymorphisms (SNPs) have been
described in the gene encoding VDR [14]. Three common
VDR-SNPs (FokI, ApaI and BsmI) have been extensively
investigated and associated with several diseases [9, 15–20].
However, although there is evidence for a genetic contribu-
tion to hypertensive disorders of pregnancy [21–23], no
previous study has examined whether VDR polymorphisms
affect the susceptibility to such disorders of pregnancy. In
this study, we examined whether three VDR polymorphisms
(FokI, ApaI and BsmI) are associated with PE or GH. We
have also examined whether these hypertensive disorders of
pregnancy are associated with VDR haplotypes.
Materials and methods
Subjects
Approval for use of human subjects was obtained from the
Institutional Review Board at the Faculty of Medicine of
Ribeirao Preto, University of Sao Paulo, Brazil and informed
consent was obtained. We studied a total of 529 pregnant (213
healthy women with uncomplicated pregnancies—HP group,
154 women with gestational hypertension—GH group, and
162 women with preeclampsia—PE group). Hypertensive
disorders were defined in accordance with the NHBPEP
(National High Blood Pressure Education Program Working
Group on High Blood Pressure in Pregnancy) [21]. GH was
defined as pregnancy-induced hypertension (C140 mmHg
systolic or C90 mmHg diastolic blood pressure on 2 or more
measurements at least 6 h apart) in a woman after 20 weeks of
gestation, and returning to normal by 12 weeks post-partum
[24]. PE was defined as gestational hypertension plus signif-
icant proteinuria (C0.3 g/24 h) [25]. No women with
pre-existing hypertension, with or without superimposed
preeclampsia, or with other comorbidity (nephropathies, co-
agulopathies, etc.) were included in the study.
At the time of clinic attendance, maternal venous blood
samples were collected. Genomic DNA was extracted
from the cellular component of 1 mL of whole blood by a
salting-out method and stored at -20 C until analyzed.
Genotyping
Genotypes for the Fok I, ApaI and BsmI were determined
by restriction fragment length polymorphism techniques as
previously described [26, 27].
Statistical analysis
The clinical characteristics of GH and PE patients were
compared with those of HP by t tests. The distribution of
genotypes for each polymorphism was assessed for devi-
ation from the Hardy–Weinberg equilibrium, and differ-
ences in genotype frequency and in allele frequency
between groups were assessed using v2-tests. In this study,
we used the PHASE v2.1 (http://www.stat.washington.edu/
stephens/software.html) [28] to estimate the haplotype
frequencies in each group. A value of P \ 0.05 was con-
sidered statistically significant. However, for the haplotype
comparisons, a corrected P value of Pc \ 0.00625 (0.05/
number of haplotypes) was considered significant to correct
for the number of comparisons made.
Results
Table 1 summarizes the characteristics of the 529 pregnant
enrolled in the present study. HP, GH, and PE groups were
similar with respect to age, ethnicity, smoking, and pri-
miparity (Table 1; all P [ 0.05). As expected, the PE and
GH groups presented higher systolic and diastolic blood
pressure compared with HP (Table 1; both P \ 0.05).
Higher proteinuria levels and lower newborn weights were
found in the PE group compared with HP and GH groups
(Table 1; all P \ 0.05).
Table 1 also shows the results of the single-locus anal-
ysis for FokI, ApaI and BsmI polymorphisms. The geno-
type distribution for the three polymorphisms studied here
showed no deviation from Hardy–Weinberg equilibrium
(all P [ 0.05, data not shown). For the three VDR poly-
morphisms studied here, we found no significant differ-
ences in genotype and allele distributions when PE or GH
were compared with HP (Table 1; all P [ 0.05).
The estimated haplotype frequencies including the three
VDR polymorphisms are shown in Table 2. In parallel with
genotypes, we found no significant differences between
groups in the overall distributions of haplotype frequencies
when GH or PE were compared with HP (Table 2; all
P [ 0.05).
Discussion
Vitamin D insufficiency is thought to be common in
pregnant women, and deficiencies in this hormone has been
linked to adverse pregnancy outcomes [3, 11, 29]. Impor-
tantly, there is evidence that vitamin D plays many
important roles in pregnancy, and maternal vitamin D
deficiency has been associated with preeclampsia [3]. This
is probably not limited to pregnancy, as vitamin D has been
shown to affect blood pressure by influencing a number of
different mechanisms involved in the regulation of arterial
blood pressure [30], and therefore vitamin D deficiency
may predispose to hypertensive disorders of pregnancy
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[4, 31, 32]. Furthermore, the expression of VDR in the
placenta suggests a role for this hormone during pregnancy
[33, 34]. However, no previous study has examined pos-
sible genetic factors related to the VDR that could affect
the susceptibility to PE or GH.
Studies examining VDR polymorphisms reported sig-
nificant associations with diabetes, arthritis, autoimmune
diseases [20, 30, 35], and essential hypertension [36]. In
the present study, our results showed that neither individual
VDR polymorphisms (FokI, ApaI and BsmI), nor VDR
haplotypes are associated with PE or GH, therefore sug-
gesting lack of relevance for these genetic variations, at
least for these hypertensive disorders of pregnancy. How-
ever, the VDR gene has more than 100,000 base pairs [14],
and our findings can not rule out the possibility that other
VDR polymorphisms affect the susceptibility to PE or GH .
A major difficulty in studying polymorphic variations in
the VDR gene is that many VDR polymorphisms have
unknown functionality. While the functionality of BsmI
and ApaI are not known, previous studies showed that the
FokI polymorphism generates two proteins with different
sizes [37], and therefore is functional. However, our find-
ings suggest that this molecular alteration is not enough
to affect the susceptibility to hypertensive disorders of
pregnancy.
There is variable prevalence of preeclampsia across
different countries, and these differences could reflect
genetic differences between those living in different
regions. In fact, there is evidence that VDR polymorphisms
are not equally distributed in different populations [26].
Therefore other studies examining the possible association
between VDR polymorphisms and hypertensive disorders
of pregnancy should be carried our in other populations.
In conclusion, our findings indicate that VDR genetic
polymorphisms (FokI, BsmI and ApaI) or haplotypes do not
exert major effects in pregnancy, and therefore do not
significantly predispose to PE or GH.
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